Compare Johnson & Johnson (JNJ) vs PubMatic Inc (PUBM) Price & Performance

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.

PUBM trades at $13.07, up 2.67% today, with a bullish technical signal from moving averages and oversold RSI conditions. The company reported a net loss of -$14.46M in 2025 despite beating Q1 2026 EPS estimates, with revenue at $282.93M. Recent news highlights product launches like AgenticOS and partnerships expanding its AI-powered ad tech reach, while analyst consensus is evenly split between Buy and Hold.

The outlook is mixed: strong cash flow and innovation in AI advertising support growth potential, but persistent negative margins and high P/E of 132 pose valuation risks. Upside exists if upcoming Q2 2026 earnings beat expectations, though competitive and macroeconomic pressures remain headwinds for profitability.